Accesswire
02 Apr 2026, 13:00 UTC · 25w ago
Verdict
Headline takes no side. We score JAGX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
An ongoing proof-of-concept study of crofelemer in pediatric intestinal failure patients showed parenteral support (PS) reductions ranging from 12% to 37%.
So whatDirect evidence of clinical efficacy in a high-need patient population is a primary driver for drug approval and future valuation.
More positive than 93% of claims this week
The global market for short bowel syndrome (SBS), including intestinal failure (IF), is estimated to reach approximately $8.0 billion by 2033.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Jaguar has submitted an abstract on the long-term safety and efficacy of the crofelemer liquid formulation for presentation at the June 2026 ESPGHAN Annual Meeting.
More positive than 64% of claims this week
Napo Pharmaceuticals is sponsoring the Annual ELITE PED-GI Congress in Abu Dhabi to support clinical collaborations and visibility for its pediatric IF program.
So whatCorporate sponsorship is a standard marketing activity with minimal direct impact on asset valuation.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported groundbreaking results in parenteral support reduction for pediatric intestinal failure and is targeting a large global market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−96.7%
Price is moving against the score
$7.06 vs $213.15 close before publication (Apr 1) · not market-adjusted
JAGX chart →
